1
|
Fardella E, Zanirato G, Magni M, Caldarelli N, Chiappella A, Dodero A, Ljevar S, Orsucci L, Re A, Usai SV, Stefoni V, Castellino C, Rossi FG, Pinto A, Carniti C, Corradini P. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas. Br J Haematol 2024; 204:1752-1756. [PMID: 38176400 DOI: 10.1111/bjh.19280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/14/2023] [Accepted: 12/19/2023] [Indexed: 01/06/2024]
Abstract
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell-free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre-treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression-free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre-treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.
Collapse
MESH Headings
- Humans
- Lymphoma, T-Cell, Peripheral/mortality
- Lymphoma, T-Cell, Peripheral/diagnosis
- Lymphoma, T-Cell, Peripheral/blood
- Lymphoma, T-Cell, Peripheral/genetics
- Male
- Female
- Middle Aged
- Aged
- Cell-Free Nucleic Acids/blood
- Prognosis
- Adult
- Biomarkers, Tumor/blood
- Prospective Studies
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Collapse
|
2
|
Zisa G, Panero A, Re A, Mennuni MG, Patti G, Pirisi M. Kounis syndrome: an underestimated emergency. Eur Ann Allergy Clin Immunol 2023; 55:294-302. [PMID: 35850501 DOI: 10.23822/eurannaci.1764-1489.260] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Summary Background. Kounis syndrome (KS) is defined as a rare cause of an acute coronary syndrome associated with systemic allergic reactions. To establish the prevalence of KS among the patients with diagnosis of anaphylaxis, we described clinical features, cardiological and allergological outcomes of patients evaluated in our allergy outpatient clinic. Methods. A retrospective study was carried out in the Allergy Unit of Novara hospital, from January 2008 to March 2020. Skin tests and in vitro tests were performed with suspected etiological agents. Results. We found 9 adults with KS (2%) out of 444 subjects who had experienced anaphylactic reactions (4/9 to Hymenoptera stings, 5/9 to drugs). Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.
Collapse
|
3
|
Antonicelli G, Ricci L, Tarraran L, Fraterrigo Garofalo S, Re A, Vasile NS, Verga F, Pirri CF, Menin B, Agostino V. Expanding the product portfolio of carbon dioxide and hydrogen-based gas fermentation with an evolved strain of Clostridium carboxidivorans. BIORESOURCE TECHNOLOGY 2023; 387:129689. [PMID: 37597573 DOI: 10.1016/j.biortech.2023.129689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/09/2023] [Accepted: 08/15/2023] [Indexed: 08/21/2023]
Abstract
CO2:H2-based gas fermentation with acetogenic Clostridium species are at an early stage of development. This work exploited the Adaptive Laboratory Evolution technique to improve the growth of C. carboxidivorans P7 on CO2 and H2. An adapted strain with decreased growth lag phase and improved biomass production was obtained. Genomic analysis revealed a conserved frameshift mutation in the catalytic subunit of the hexameric hydrogenase gene. The resulted truncated protein variant, most likely lacking its functionality, suggests that other hydrogenases might be more efficient for H2-based growth of this strain. Furthermore, the adapted strain generated hexanol as primary fermentation product. For the first time, hexanol was produced directly from CO2:H2 blend, achieving the highest maximum productivity reported so far via gas fermentation. Traces of valerate, pentanol, eptanol and octanol were observed in the fermentation broth. The adapted strain shows promising to enrich the product spectrum targetable by future gas fermentation processes.
Collapse
|
4
|
Mongelli A, Panunzi S, Nesta M, Gottardi Zamperla M, Atlante S, Barbi V, Mongiardini V, Ferraro F, De Martino S, Cis L, Re A, Maltese S, Bachetti T, La Rovere MT, Martelli F, Pesce M, Nanni S, Massetti M, Pontecorvi A, Farsetti A, Gaetano C. Distinguishable DNA methylation defines a cardiac-specific epigenetic clock. Clin Epigenetics 2023; 15:53. [PMID: 36991505 PMCID: PMC10053964 DOI: 10.1186/s13148-023-01467-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Accepted: 03/18/2023] [Indexed: 03/31/2023] Open
Abstract
BACKGROUND The present study investigates whether epigenetic differences emerge in the heart of patients undergoing cardiac surgery for an aortic valvular replacement (AVR) or coronary artery bypass graft (CABG). An algorithm is also established to determine how the pathophysiological condition might influence the human biological cardiac age. RESULTS Blood samples and cardiac auricles were collected from patients who underwent cardiac procedures: 94 AVR and 289 CABG. The CpGs from three independent blood-derived biological clocks were selected to design a new blood- and the first cardiac-specific clocks. Specifically, 31 CpGs from six age-related genes, ELOVL2, EDARADD, ITGA2B, ASPA, PDE4C, and FHL2, were used to construct the tissue-tailored clocks. The best-fitting variables were combined to define new cardiac- and blood-tailored clocks validated through neural network analysis and elastic regression. In addition, telomere length (TL) was measured by qPCR. These new methods revealed a similarity between chronological and biological age in the blood and heart; the average TL was significantly higher in the heart than in the blood. In addition, the cardiac clock discriminated well between AVR and CABG and was sensitive to cardiovascular risk factors such as obesity and smoking. Moreover, the cardiac-specific clock identified an AVR patient's subgroup whose accelerated bioage correlated with the altered ventricular parameters, including left ventricular diastolic and systolic volume. CONCLUSION This study reports on applying a method to evaluate the cardiac biological age revealing epigenetic features that separate subgroups of AVR and CABG.
Collapse
|
5
|
Appel S, Bagdasarian Z, Basilico D, Bellini G, Benziger J, Biondi R, Caccianiga B, Calaprice F, Caminata A, Cavalcante P, Chepurnov A, D'Angelo D, Derbin A, Di Giacinto A, Di Marcello V, Ding XF, Di Ludovico A, Di Noto L, Drachnev I, Franco D, Galbiati C, Ghiano C, Giammarchi M, Goretti A, Göttel AS, Gromov M, Guffanti D, Ianni A, Ianni A, Jany A, Kobychev V, Korga G, Kumaran S, Laubenstein M, Litvinovich E, Lombardi P, Lomskaya I, Ludhova L, Lukyanchenko G, Machulin I, Martyn J, Meroni E, Miramonti L, Misiaszek M, Muratova V, Nugmanov R, Oberauer L, Orekhov V, Ortica F, Pallavicini M, Papp L, Pelicci L, Penek Ö, Pietrofaccia L, Pilipenko N, Pocar A, Raikov G, Ranalli MT, Ranucci G, Razeto A, Re A, Redchuk M, Rossi N, Schönert S, Semenov D, Settanta G, Skorokhvatov M, Singhal A, Smirnov O, Sotnikov A, Tartaglia R, Testera G, Unzhakov E, Villante FL, Vishneva A, Vogelaar RB, von Feilitzsch F, Wojcik M, Wurm M, Zavatarelli S, Zuber K, Zuzel G. Improved Measurement of Solar Neutrinos from the Carbon-Nitrogen-Oxygen Cycle by Borexino and Its Implications for the Standard Solar Model. PHYSICAL REVIEW LETTERS 2022; 129:252701. [PMID: 36608219 DOI: 10.1103/physrevlett.129.252701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 09/01/2022] [Accepted: 10/05/2022] [Indexed: 06/17/2023]
Abstract
We present an improved measurement of the carbon-nitrogen-oxygen (CNO) solar neutrino interaction rate at Earth obtained with the complete Borexino Phase-III dataset. The measured rate, R_{CNO}=6.7_{-0.8}^{+2.0} counts/(day×100 tonnes), allows us to exclude the absence of the CNO signal with about 7σ C.L. The correspondent CNO neutrino flux is 6.6_{-0.9}^{+2.0}×10^{8} cm^{-2} s^{-1}, taking into account the neutrino flavor conversion. We use the new CNO measurement to evaluate the C and N abundances in the Sun with respect to the H abundance for the first time with solar neutrinos. Our result of N_{CN}=(5.78_{-1.00}^{+1.86})×10^{-4} displays a ∼2σ tension with the "low-metallicity" spectroscopic photospheric measurements. Furthermore, our result used together with the ^{7}Be and ^{8}B solar neutrino fluxes, also measured by Borexino, permits us to disfavor at 3.1σ C.L. the "low-metallicity" standard solar model B16-AGSS09met as an alternative to the "high-metallicity" standard solar model B16-GS98.
Collapse
|
6
|
Iezzi M, Cusumano D, Piccari D, Menna S, Catucci F, D'Aviero A, Re A, Di Dio C, Quaranta F, Boschetti A, Marras M, Piro D, Votta C, Sanna E, Flore C, Mattiucci G, Valentini V. PO-1483 A predictive model to quantify the dosimetric impact of inter-fraction variability in breast cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03447-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Boschetti A, Votta C, Re A, Piro D, Marras M, D'Aviero A, Catucci F, Cusumano D, Di Dio C, Menna S, Iezzi M, Quaranta F, Flore C, Sanna E, Piccari D, Mattiucci G, Valentini V. PD-0336 Evaluation of a deep-learning segmentation software in thoracic organs at risk: an early analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02829-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Piro D, Marras M, D'Aviero A, Boschetti A, Votta C, Re A, Catucci F, Cusumano D, Di Dio C, Menna S, Iezzi M, Quaranta F, Flore C, Sanna E, Piccari D, Mattiucci G, Valentini V. PO-1887 Validation of deep learning auto-segmentation in pelvic organs at risk: a preliminary analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03850-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Agostini M, Altenmüller K, Appel S, Atroshchenko V, Bagdasarian Z, Basilico D, Bellini G, Benziger J, Biondi R, Bravo D, Caccianiga B, Calaprice F, Caminata A, Cavalcante P, Chepurnov A, D'Angelo D, Davini S, Derbin A, Di Giacinto A, Di Marcello V, Ding XF, Di Ludovico A, Di Noto L, Drachnev I, Formozov A, Franco D, Galbiati C, Ghiano C, Giammarchi M, Goretti A, Göttel AS, Gromov M, Guffanti D, Ianni A, Ianni A, Jany A, Jeschke D, Kobychev V, Korga G, Kumaran S, Laubenstein M, Litvinovich E, Lombardi P, Lomskaya I, Ludhova L, Lukyanchenko G, Lukyanchenko L, Machulin I, Martyn J, Meroni E, Meyer M, Miramonti L, Misiaszek M, Muratova V, Neumair B, Nieslony M, Nugmanov R, Oberauer L, Orekhov V, Ortica F, Pallavicini M, Papp L, Pelicci L, Penek Ö, Pietrofaccia L, Pilipenko N, Pocar A, Raikov G, Ranalli MT, Ranucci G, Razeto A, Re A, Redchuk M, Romani A, Rossi N, Schönert S, Semenov D, Settanta G, Skorokhvatov M, Singhal A, Smirnov O, Sotnikov A, Suvorov Y, Tartaglia R, Testera G, Thurn J, Unzhakov E, Vishneva A, Vogelaar RB, von Feilitzsch F, Wessel A, Wojcik M, Wonsak B, Wurm M, Zavatarelli S, Zuber K, Zuzel G. First Directional Measurement of Sub-MeV Solar Neutrinos with Borexino. PHYSICAL REVIEW LETTERS 2022; 128:091803. [PMID: 35302807 DOI: 10.1103/physrevlett.128.091803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 01/25/2022] [Indexed: 06/14/2023]
Abstract
We report the measurement of sub-MeV solar neutrinos through the use of their associated Cherenkov radiation, performed with the Borexino detector at the Laboratori Nazionali del Gran Sasso. The measurement is achieved using a novel technique that correlates individual photon hits of events to the known position of the Sun. In an energy window between 0.54 to 0.74 MeV, selected using the dominant scintillation light, we have measured 10 887_{-2103}^{+2386}(stat)±947(syst) (68% confidence interval) solar neutrinos out of 19 904 total events. This corresponds to a ^{7}Be neutrino interaction rate of 51.6_{-12.5}^{+13.9} counts/(day·100 ton), which is in agreement with the standard solar model predictions and the previous spectroscopic results of Borexino. The no-neutrino hypothesis can be excluded with >5σ confidence level. For the first time, we have demonstrated the possibility of utilizing the directional Cherenkov information for sub-MeV solar neutrinos, in a large-scale, high light yield liquid scintillator detector. This measurement provides an experimental proof of principle for future hybrid event reconstruction using both Cherenkov and scintillation signatures simultaneously.
Collapse
|
10
|
Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A, Chiorini JA, Su HC, Cohen JI, Burbelo PD, Rossi G, Notarangelo LD. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer J 2021; 11:151. [PMID: 34521813 PMCID: PMC8438656 DOI: 10.1038/s41408-021-00546-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 08/14/2021] [Accepted: 08/27/2021] [Indexed: 12/17/2022] Open
Abstract
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
Collapse
|
11
|
Pezzulla D, Macchia G, Cilla S, Boccardi M, Re A, Bonome P, Picardi V, Ferro M, Romano C, Buwenge M, Cammelli S, Valentini V, Valenti V, Morganti A, Deodato F. PD-0887 VMAT Radiotherapy boost in oligometastatic patients with Spinal Metastases: a dose escalation study. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07166-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Bisello S, Arcelli A, Deodato F, Dominsky N, Tarantino G, Ntreta M, Cilla S, Siepe G, Cavallini L, Pezzulla D, Alitto A, Re A, Cammelli S, Cortesi A, Romeo A, Frezza G, Morganti A, Macchia G, Buwenge M. PO-1392 Salvage radiotherapy of prostate cancer: a risk stratification system based on prognostic factors. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07843-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Zamagni A, Bonetti M, Buwenge M, Ntreta M, Tolento G, Cammelli S, Donati C, Lodi Rizzini E, Boccardi M, Re A, Deodato F, Cilla S, Macchia G, Morganti A. PO-1394 Stereotactic body radiotherapy for prostate cancer lymph node metastases: a systematic review. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07845-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Bisello S, Arcelli A, Deodato F, Dominsky N, Tarantino G, Ntreta M, Cilla S, Siepe G, Cavallini L, Pezzulla D, Alitto A, Re A, Cammelli S, Cortesi A, Romeo A, Frezza G, Morganti A, Macchia G, Buwenge M. PO-1380 Adjuvant radiotherapy of prostate cancer: a risk stratification system based on prognostic factors. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07831-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Tucci A, Musuraca G, Cavallo F, Zilioli VR, Zanni M, Pelliccia S, Mannina D, Michieli M, Vallisa D, Tani M, Merli F, Re F, Marcheselli L, Campostrini G, Pagani C, Grimaldi D, Liardo EV, Re A, Cox MC, Rossi G. AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.99_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Chiappella A, Carniti C, Re A, Castellino C, Evangelista A, Ciancia R, Orsucci L, Pinto A, Usai SV, Arcari A, Ilariucci F, Rossi FG, Benedetti F, Flenghi L, Ghiggi C, Molinari AL, Stefoni V, Volpetti S, Zilioli VR, Ballerini F, Bruna R, Cavallo F, Musuraca G, Patti C, Re F, Tani M, Varettoni M, Zanni M, Dodero A, Pileri SA, Ciccone G, Corradini P. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.130_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
17
|
Tucci A, Merli F, Fabbri A, Mancuso S, Sartori R, Storti S, Luminari S, Mammi C, Marcheselli L, Arcari A, Cavallo F, Zilioli VR, Bottelli C, Re A, Gini G, Cox MC, Puccini B, Pagani C, Balzarotti M, Spina M, Rossi G. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.95_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
18
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
19
|
Re A, Cilla S, Ferro M, Ianiro A, Macchia G, Picardi V, Boccardi M, Cammelli S, Romano C, D'Addario D, Buwenge M, Mignogna S, Ferro M, Valentini V, Sallustio G, Morganti A, Deodato F. PO-0794: Induction chemotherapy followed by moderately accelerated IMRT in head and neck cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00811-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Ferro M, Ianiro A, Re A, Macchia G, Cilla S, Picardi V, Boccardi M, Ferro M, Cammelli S, Romano C, Bisello S, Buwenge M, Mignogna S, Giglio G, Cucci E, Valentini V, Morganti A, Deodato F. OC-0091: SIB accelerated RT and concomitant TMZ in GBM patients: results of a phase I study (ISIDE BT-2). Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00117-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Alitto A, Buwenge M, Macchia G, Ntreta M, Siepe G, Galofaro E, Bertini F, Ferioli M, Mazzeo E, Ippolito E, Mantini G, Ferro M, Re A, Cilla S, Valentini V, Deodato F, Morganti A, Cammelli S. PO-1185: Results of prostate cancer patients treated by integrated boost to dominant intraprostatic lesion. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01203-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Deodato F, Re A, Ianiro A, Ferro M, Macchia G, Picardi V, Boccardi M, Buwenge M, Assalone P, Berardinelli F, Maselli G, Cammelli S, Ferro M, Romano C, Mignogna S, Valentini V, Morganti A, Cilla S. PD-0667: Early analysis from two phase I trials on SBRT of isolated nodal recurrences in prostate patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00689-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Ferioli M, Panni V, Galuppi A, Zamagni A, Buwenge M, Macchia G, Deodato F, Re A, Boccardi M, Cilla S, Fanti S, Morganti A, Cammelli S. PO-1134: 18F-FDG-PET/CT role in the adjuvant setting of endometrial cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01151-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Re A, Picardi V, Deodato F, Ianiro A, Cilla S, Boccardi M, Ferro M, Arcelli A, Buwenge M, Cammelli S, Romano C, Restaino G, Ferro M, Specchia M, Guido A, Mignogna S, Valentini V, Morganti A, Macchia G. PO-1083: Efficacy and tolerance of VMAT-SIB intensified neoadjuvant chemoradiation in rectal cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01100-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Macchia G, Cerrotta A, Deodato F, Pappalardi B, Re A, Santoni R, Campitelli M, Scambia G, Valentini V, Aristei C, Ferrandina G. PO-1116: Cervical cancer patterns of care in italy: a radiation oncology survey of mito and airo gyn groups. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01133-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|